NOV 23, 2019 11:13 PM PST

Drug Seeks To Target Treatment-Resistant Epilepsy

WRITTEN BY: Nouran Amin

Ever imagined a world where you cannot shower alone, drive by yourself, and even go to work in fear of having the next seizure that can incapacitate you? Unfortunately, this is the life of many patients with epilepsy—a chronic seizure condition. To bring hope, researchers at John Hopkins University found that an investigational drug called ‘cenobamate’ can reduce seizures by 55%.

Although there exists more than 20 anti-seizure drugs on the market, approximately half of epilepsy patients don’t become seizure-free on these medications. Cenobamate, which is not yet approved by the Food and Drug Administration (FDA), aims to target treatment-resistant epilepsy. In order for cenobamate to be approved, it must be safely administered and evaluated in 30,000 epileptic patients

“A quarter of the patients I treat with this drug [cenobamate] who were disabled by frequent partial-onset (focal) seizures now have been seizure-free for several years,” says lead investigator Gregory Krauss, M.D., professor of neurology at the Johns Hopkins University School of Medicine. “It is wonderful to see the improvement in many of my patients’ lives. They have improved confidence and can live more normal lives. Many can now work, and both patients and caretakers can be more independent.”

Learn more about epilepsy:

In the study, regular treatment was stimulated and clinical participants were given 100, 200 or 400 milligrams of cenobamate or a placebo pill with the cenobamate dose increasing for up to six weeks until the desired testing dose was reached. However, to meet FDA ethical standards, participants must remain on their regularly prescribed anti-seizure medication.

Findings of the study were published in The Lancet Neurology.

Source: Hopkins Medicine

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Advancing Nanocontainers for Drug Delivery
Nanocontainers work by delivering drugs to a localized region in the body, many chemotherapeutics work in that matter. The high specificity of this drug de...
JAN 21, 2020
Genetics & Genomics
JAN 21, 2020
Can CRISPR Replace Antibiotics?
Antibiotic-resistant infections claim around 700,000 lives per year, with estimates saying that this number could swell to 10 million by 2050 (Jacobs: 2019...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Darobactin: Promising New Drug to Combat Antibiotic Resistance
Every year, around 700,000 people are estimated to die from drug-resistant infections thanks to our overuse of antibiotics both in agriculture and medicine...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
JAN 21, 2020
Genetics & Genomics
JAN 21, 2020
Finding a Way to Treat Dangerous Protein Aggregates
The scientists are hopeful that this work will lead to new therapeutics for neurodegenerative disease....
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Effective Therapeutic Approved for Migraines
The U.S Food and Drug Administration has now approved a new medication for migraines. The drug is called ‘ubrogepant (Ubrelvy)’ and comes in th...
Loading Comments...